Literature DB >> 15541309

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Alexander Zimprich1, Saskia Biskup, Petra Leitner, Peter Lichtner, Matthew Farrer, Sarah Lincoln, Jennifer Kachergus, Mary Hulihan, Ryan J Uitti, Donald B Calne, A Jon Stoessl, Ronald F Pfeiffer, Nadja Patenge, Iria Carballo Carbajal, Peter Vieregge, Friedrich Asmus, Bertram Müller-Myhsok, Dennis W Dickson, Thomas Meitinger, Tim M Strom, Zbigniew K Wszolek, Thomas Gasser.   

Abstract

We have previously linked families with autosomal-dominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8). By high-resolution recombination mapping and candidate gene sequencing in 46 families, we have found six disease-segregating mutations (five missense and one putative splice site mutation) in a gene encoding a large, multifunctional protein, LRRK2 (leucine-rich repeat kinase 2). It belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains. Within affected carriers of families A and D, six post mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies. These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathology, and progressive supranuclear palsy-like pathology. Clinical diagnoses of Parkinsonism with dementia or amyotrophy or both, with their associated pathologies, are also noted. Hence, LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541309     DOI: 10.1016/j.neuron.2004.11.005

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  1062 in total

1.  Age at onset in LRRK2-associated PD is modified by SNCA variants.

Authors:  Teresa Botta-Orfila; Mario Ezquerra; Pau Pastor; Rubén Fernández-Santiago; Claustre Pont-Sunyer; Yaroslau Compta; Oswaldo Lorenzo-Betancor; Lluis Samaranch; Maria José Martí; Francesc Valldeoriola; Matilde Calopa; Manel Fernández; Miquel Aguilar; Oriol de Fabregas; Jorge Hernández-Vara; Eduard Tolosa
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

Review 2.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

3.  LRRK2 is involved in the IFN-gamma response and host response to pathogens.

Authors:  Agnès Gardet; Yair Benita; Chun Li; Bruce E Sands; Isabel Ballester; Christine Stevens; Joshua R Korzenik; John D Rioux; Mark J Daly; Ramnik J Xavier; Daniel K Podolsky
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

Review 4.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 5.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

Review 6.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

7.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 8.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

Review 9.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 10.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.